Cure8 research brief
Pregnancy planning and medication decisions are important questions for people with IBD. This study suggests continuing certain IBD treatments through conception and pregnancy did not show drug-related harm in this Brazilian cohort, and disease activity at conception related to some neonatal outcomes.
Pregnant people with IBD, people planning pregnancy, pediatric follow-up teams, and clinicians who manage IBD in pregnancy.
The study followed 25 pregnancies from a cohort of 329 IBD patients treated at a single clinic. Roughly half of pregnancies began with active endoscopic disease and half in remission. Patients continued prescribed therapies, including anti-TNF biologics and immunosuppressants.
The authors report that maternal disease activity at conception was associated with lower birth weight and lower Apgar scores compared with pregnancies starting in remission, but prematurity was not observed. No drug-related adverse effects were reported for mothers or infants, and no developmental abnormalities were noted in 2-year postpartum follow-up.
What to watch for: This is a single-center, retrospective analysis with a small pregnancy sample (25 pregnancies) within a larger registry. The abstract provides study conclusions but not full methodological detail here; full paper review would be needed for assessment of confounding factors, definitions of outcomes, and exact medications/doses.
The report is a retrospective, single-clinic cohort with only 25 pregnancies reported; that limits generalizability. The abstract-format source provides summary results but not full methodological or statistical detail.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Subcutaneous infliximab may let children on infliximab avoid regular IV infusions while keeping drug levels high and maintaining remission. Results are relevant to families and clinicians considering switching pediatric...
This study reports that combining an anti-TNF-α drug with vedolizumab helped many children with IBD who failed single-biologic therapy achieve clinical, endoscopic, and histologic improvement. It also notes serious...
Patients on biologic therapy often have drug levels and antidrug antibodies measured to guide care. This study suggests prior biologic history, disease type (UC vs CD) and which biologic is currently used may affect...
